You are here: Industry Insights > NASH

News List

NorthSea Therapeutics secures funding to develop NASH drug pharmaceutical-technology
December 14, 2017
Dutch biotech firm NorthSea Therapeutics has secured a €25m Series A funding to develop a structurally engineered fatty acid (SEFA), icosabutate, for treating non-alcoholic steatohepatitis (NASH).
NorthSea Therapeutics Secures €25 Million Funding for Clinical Development of Promising NASH Drug b3cnewswire
December 13, 2017
NorthSea Therapeutics B.V. a newly established Dutch biotech company, announced today the completion of a €25m Series A funding for the development of icosabutate, a structurally engineered fatty acid (‘SEFA’) as a novel, oral approach for the treatment
Galectin Therapeutics' share value plummets by half after NASH drug failure pharmafile
December 07, 2017
Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis (NASH) cirrhosis, had missed its primary endpoint in a Phase 2b trial.
Histoindex receives Frost & Sullivan 2017 Asia- Pacific best Practices award biospectrumasia
October 09, 2017
The award is a testament of the achievements by HistoIndex and the impact of its proprietary technologies on aiding clinical diagnosis and the development of NASH therapeutics.
Allergan posts disappointing data in NASH pharmafile
September 26, 2017
It was only last year that Allergan decided to cough up $1.7 billion to acquire Tobira Therapeutics, with the main driver being its lead candidate for NASH, cenicriviroc (CVC).
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating l worldpharmanews
August 28, 2017
Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335, acquired from Pharmaxis in May 2015
Upstart Blade nabs Bristol-Myers Squibb research executive as new R&D lead fiercebiotech
August 22, 2017
Nabbing a BMS executive is a big coup for Blade, a small biotech betting big on the NASH space.
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH worldpharmanews
May 05, 2017
Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercialization of emricasan, under the option, collaboration and license agreement signed w
Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH americanpharmaceuticalreview
May 04, 2017
Can-Fite BioPharma provided an update on a Phase II clinical trial to evaluate its liver drug candidate Namodenoson (CF102) in the treatment of non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH).
BMS Phase II study in non-alcoholic steatohepatitis a success europeanpharmaceuticalreview
April 25, 2017
BMS-986036 is a pegylated analogue of human fibroblast growth factor 21, a key regulator of metabolism. In preclinical models of non-alcoholic steatohepatitis (NASH), BMS-986036 improved steatosis, inflammation, hepatocyte ballooning, and fibrosis.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page